iOnctura to Showcase Late-Breaking Findings on Roginolisib for NSCLC at SITC 2026#USA#Phoenix#NSCLC#iOnctura#roginolisib
iOnctura to Showcase Late-Breaking Findings on Roginolisib for NSCLC at SITC 2026
iOnctura is set to present critical findings regarding roginolisib in treating immunotherapy-resistant NSCLC at SITC 2026, highlighting its innovative approach.
third-news.com
October 29, 2026 at 2:23 PM
iOnctura to Showcase Late-Breaking Findings on Roginolisib for NSCLC at SITC 2026#USA#Phoenix#NSCLC#iOnctura#roginolisib
Phase 1 data showed the PI3Kδ inhibitor roginolisib demonstrated preliminary antitumor activity and a safety profile that supports further evaluation in patients with advanced or metastatic cancers, including metastatic uveal melanoma #melsm #oncology www.onclive.com/view/roginol...
Roginolisib Demonstrates Preliminary Activity in Metastatic Uveal Melanoma | OncLive
Phase 1 data support continued investigation of roginolisib in advanced cancers, including metastatic uveal melanoma.
www.onclive.com
October 22, 2026 at 5:05 PM
Phase 1 data showed the PI3Kδ inhibitor roginolisib demonstrated preliminary antitumor activity and a safety profile that supports further evaluation in patients with advanced or metastatic cancers, including metastatic uveal melanoma #melsm #oncology www.onclive.com/view/roginol...
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress. www.dovepress.com/roginolisib-... #hvhebron #hemat [Text complet]
Roginolisib in Combination with Ruxolitinib in Patients with Myelofibr | OTT | Dove Medical Press
This study is to evaluate the tolerability of roginolisib when combined with an approved JAK inhibitor in MF patients, HEMA-MED trial study.
www.dovepress.com
October 20, 2026 at 12:32 PM
Roginolisib in Combination with JAK Inhibitors in Patients with Myelofibrosis Who are Unresponsive to Approved JAK Inhibitors (Study HEMA-MED) - A Trial in Progress. www.dovepress.com/roginolisib-... #hvhebron #hemat [Text complet]
💊 Cancer drug passes first human safety test
A first trial in advanced cancer, led from Siena, Italy, found serious side effects in 3 of 44 patients on roginolisib. None needed a lower dose. Early hope for eye melanoma.
🔗 doi.org/10.1038/s41467-026-77358-7
#Cancer #Oncology 🧪
A first trial in advanced cancer, led from Siena, Italy, found serious side effects in 3 of 44 patients on roginolisib. None needed a lower dose. Early hope for eye melanoma.
🔗 doi.org/10.1038/s41467-026-77358-7
#Cancer #Oncology 🧪
The conformation-selective PI3Kδ inhibitor roginolisib in patients with advanced or metastatic cancer, including metastatic uveal melanoma: first-in-human clinical trial - Nature Communications
First generation inhibitors of phosphatidylinositol 3-kinase delta (PI3Kδ) had limited selectivity due to the conserved ATP binding pocket, resulting in toxicity when used as anti-cancer agent. Here, ...
doi.org
October 18, 2026 at 7:12 AM
💊 Cancer drug passes first human safety test
A first trial in advanced cancer, led from Siena, Italy, found serious side effects in 3 of 44 patients on roginolisib. None needed a lower dose. Early hope for eye melanoma.
🔗 doi.org/10.1038/s41467-026-77358-7
#Cancer #Oncology 🧪
A first trial in advanced cancer, led from Siena, Italy, found serious side effects in 3 of 44 patients on roginolisib. None needed a lower dose. Early hope for eye melanoma.
🔗 doi.org/10.1038/s41467-026-77358-7
#Cancer #Oncology 🧪
RRIDs were included in this in Nature Communications paper. Thanks for making your methods matter! #BetterScience #OpenResearch #OpenScience
PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12 - Nature Communications
In this work. Vadas et al. report how Roginolisib, a phosphoinositide 3-kinase delta specific inhibitor, locks the enzyme in an inactive conformation, providing high potency and specificity. This binding mode results in reduced phosphatidylinositol 3,4,5-trisphosphate formation in tumour samples of CLL patients receiving Roginolisib.
doi.org
October 16, 2026 at 7:01 AM
RRIDs were included in this in Nature Communications paper. Thanks for making your methods matter! #BetterScience #OpenResearch #OpenScience
iOnctura's roginolisib shows a near-threefold OS improvement in metastatic uveal melanoma versus historical controls, supported by dual Nature Communications papers detailing its novel PI3Kδ binding mechanism.
iOnctura's roginolisib gets dual Nature Communications papers
Two peer-reviewed studies detail roginolisib's novel PI3Kδ binding mode and report a near-threefold OS improvement in metastatic uveal melanoma over historical controls.
biotech.disruptsmedia.com
October 13, 2026 at 6:37 AM
iOnctura's roginolisib shows a near-threefold OS improvement in metastatic uveal melanoma versus historical controls, supported by dual Nature Communications papers detailing its novel PI3Kδ binding mechanism.
PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12 #nature #MassSpecRSS
PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12 - Nature Communications
In this work. Vadas et al. report how Roginolisib, a phosphoinositide 3-kinase delta specific inhibitor, locks the enzyme in an inactive conformation, providing high potency and specificity. This binding mode results in reduced phosphatidylinositol 3,4,5-trisphosphate formation in tumour samples of CLL patients receiving Roginolisib.
dlvr.it
October 9, 2026 at 4:06 PM
PI3Kδ is selectively inhibited by roginolisib by stabilizing the C-terminal helix kα12 #nature #MassSpecRSS
Hope on the horizon: iOnctura expands its Phase II roginolisib trial into the US, enrolling patients with metastatic uveal melanoma.
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
September 19, 2025 at 6:03 PM
Hope on the horizon: iOnctura expands its Phase II roginolisib trial into the US, enrolling patients with metastatic uveal melanoma.
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
Read more 👉 https://wp-ionctura-2025.s3.eu-west-2.amazonaws.com/media/2025/09/iOnctura-clinical-trial-update-09.09.25.pdf
#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
September 9, 2025 at 8:26 AM
#IORnews
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
A collaborative team from IOR, Dana-Farber Cancer Institute (Harvard Medical School), and biotech iOnctura reports that the novel drug roginolisib may boost the effectiveness of venetoclax in blood cancers such as DLBCL, mantle cell lymphoma, and CLL.
Learn more: tinyurl.com/ytybcbr8
🔬 New research from the Taskén lab, Giusy Di Conza and colleagues show that roginolisib inhibits leukemic cells while preserving key T-cell functions, highlighting its potential as a safer alternative to current PI3K inhibitors.
🔓https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.70203
🔓https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.70203
June 26, 2026 at 12:11 PM
🔬 New research from the Taskén lab, Giusy Di Conza and colleagues show that roginolisib inhibits leukemic cells while preserving key T-cell functions, highlighting its potential as a safer alternative to current PI3K inhibitors.
🔓https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.70203
🔓https://febs.onlinelibrary.wiley.com/doi/10.1002/1878-0261.70203
#iOnctura #uvealmelanoma #uvealmelanomapatients #uvealmelanomatherapy #phase1study #roginolisib #phase1#DIONE01study #clinicalactivity #longtermsafety #ESMO #EuropeanSocietyforMedicalOncology #ImmunoOncology #allostericbindingmechanism #phase2study #OCULE01study
pharmatimes.com/news/ionctur...
pharmatimes.com/news/ionctur...
iOnctura achieves new clinical milestones in uveal melanoma therapy - PharmaTimes
Successful phase 1 study highlights potential of roginolisib
pharmatimes.com
December 11, 2024 at 2:05 PM
iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference#United_States#cancer_therapy#San_Francisco#iOnctura#roginolisib
iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference
Catherine Pickering, CEO of iOnctura, will discuss the company's innovative cancer therapies at the upcoming J.P. Morgan Healthcare Conference in January.
third-news.com
January 9, 2026 at 1:12 PM
iOnctura CEO Catherine Pickering to Present at 2026 J.P. Morgan Healthcare Conference#United_States#cancer_therapy#San_Francisco#iOnctura#roginolisib
iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial#Switzerland#Geneva#Myelofibrosis#roginolisib#ASH2025
iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial
iOnctura announces the initiation of its Phase I/II trial evaluating roginolisib for myelofibrosis patients not responding to JAK inhibitors.
third-news.com
December 4, 2025 at 8:12 AM
iOnctura Advances Myelofibrosis Treatment with Phase I/II Roginolisib Trial#Switzerland#Geneva#Myelofibrosis#roginolisib#ASH2025
iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options#United_States#Cambridge#oncology#iOnctura#roginolisib
iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options
iOnctura's expansion of roginolisib trials to the US aims to revolutionize cancer treatment strategies for hard-to-treat cancers.
third-news.com
September 9, 2025 at 7:16 AM
iOnctura Expands Roginolisib Trials in the US to Enhance Cancer Treatment Options#United_States#Cambridge#oncology#iOnctura#roginolisib
iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations#oncology#Netherlands#Amsterdam#iOnctura#roginolisib
iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations
iOnctura announces the appointment of Steven Sciuto as CFO and Michelle Tsai as COO, enhancing leadership to boost oncology portfolio success.
third-news.com
June 2, 2025 at 7:32 AM
iOnctura Strengthens Leadership Team with Key New Appointments to Drive Oncology Innovations#oncology#Netherlands#Amsterdam#iOnctura#roginolisib
iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib#Netherlands#Amsterdam#Lung_Cancer#iOnctura#roginolisib
iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib
iOnctura has initiated a Phase I/II study targeting advanced non-small cell lung cancer, exploring the effectiveness of roginolisib combined with dostarlimab and chemotherapy.
third-news.com
May 8, 2025 at 8:08 AM
iOnctura Launches Phase I/II Study for Advanced Lung Cancer Treatment with Roginolisib#Netherlands#Amsterdam#Lung_Cancer#iOnctura#roginolisib
iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment#None#Amsterdam#iOnctura#roginolisib#uveal_melanoma
iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment
iOnctura has initiated a Phase II study for roginolisib, aimed at treating metastatic uveal melanoma, garnering orphan drug designation in Europe.
third-news.com
March 20, 2025 at 10:39 AM
iOnctura Launches Phase II Study for Metastatic Uveal Melanoma Treatment#None#Amsterdam#iOnctura#roginolisib#uveal_melanoma
iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment#Netherlands#Amsterdam#iOnctura#roginolisib#uveal_melanoma
iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment
iOnctura has announced promising clinical results for roginolisib, a new treatment for uveal melanoma, showing improved survival rates.
third-news.com
December 11, 2024 at 10:42 AM
iOnctura Achieves Significant Clinical Advancements in Uveal Melanoma Treatment#Netherlands#Amsterdam#iOnctura#roginolisib#uveal_melanoma
iOctura recently launched a randomized Phase I/II study investigating whether roginolisib, combined with dostarlimab, can help reprogram the immune system to prevent or reverse resistance in non-small cell lung cancer. #lungcancer
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
iOnctura commences randomized Phase I/II study in non-small cell lung cancer
/PRNewswire/ -- iOnctura, a clinical-stage biopharmaceutical company combating neglected and hard-to-treat cancers, today announces it has dosed the first...
www.prnewswire.com
May 16, 2025 at 2:04 PM
iOctura recently launched a randomized Phase I/II study investigating whether roginolisib, combined with dostarlimab, can help reprogram the immune system to prevent or reverse resistance in non-small cell lung cancer. #lungcancer
www.prnewswire.com/news-release...
www.prnewswire.com/news-release...
The results showing the benefit of combining the non-ATP competitive Pi3Kδ inhibitor roginolisib with venetoclax in lymphoid tumors are out in Haematologica. A collaboration of @iorbellinzona.bsky.social, Jennifer Brown’s group and iOnctura colleagues. haematologica.org/newsletter/v...
Early View
| Haematologica
haematologica.org
June 20, 2025 at 5:37 AM
The results showing the benefit of combining the non-ATP competitive Pi3Kδ inhibitor roginolisib with venetoclax in lymphoid tumors are out in Haematologica. A collaboration of @iorbellinzona.bsky.social, Jennifer Brown’s group and iOnctura colleagues. haematologica.org/newsletter/v...
